GC said Tuesday that it has signed an exclusive licensing agreement in the greater China area to commercialize Hunterase, a Hunter Syndrome drug, with CANbridge Pharmaceuticals, a Chinese-based drug company.
Under the accord, CANbridge will have exclusive rights to develop and commercialize Hunterase in the greater China area. The two companies agreed not to disclose the size of the contract.
Developed by GC, Hunterase is a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy for treating Hunter syndrome. The company is marketing the product in more than 10 countries.
In China, however, there are no drugs approved for treating Hunter syndrome.
“Hunterase is the first rare disease drug CANbridge will commercialize in China,” CANbridge Pharmaceuticals CEO and Chairman James Xue said. Like so many rare diseases, there is no treatment for Hunter syndrome in China, short of palliative care.”
The company looks forward to the possibility of bringing Hunterase to Hunter syndrome patients and their families, Xue said.
GC President Huh Eun-chu, also said, “We are delighted to enhance the value of Hunterase through this partnership further. Our ultimate goal is to make a meaningful difference in the lives of those with Hunter syndrome in all markets.”
<© Korea Biomedical Review, All rights reserved.>